Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment (NCT04617522)
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
🩺 Plain-English Summary (8th-Grade Level)
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Who can join: Review the eligibility criteria below.
Location: Pacific Shores Medical Group — Long Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Pacific Shores Medical Group — Long Beach, California
- Christiana Care Health Services — Newark, Delaware
- University of Maryland — Baltimore, Maryland
- NEXT Austin — Austin, Texas
- Oncology Consultants, P.A. — Houston, Texas
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas
- Texas Liver Institute — San Antonio, Texas
- NEXT Oncology — San Antonio, Texas
- Institut Bergonie Medical Oncology — Bordeaux,
- Centre Leon Berard — Lyon,
- Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain — Saint-Herblain,
- Instituto Europeo di Oncologia — Milan,
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale — Naples,
- Institut Català d'Oncologia - L'Hospitalet de Llobregat — Barcelona,
- Hospital Universitario Virgen del Rocío — Seville,
📞 Contact the Study Coordinator
Phone: 1-833-445-3230 (GILEAD-0)
Email: GileadClinicalTrials@gilead.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumor
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors — New Haven, Connecticut
Explore by condition: All Advanced or Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.